The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia
Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. Blood Reviews 2019, 43: 100650. PMID: 31883804, DOI: 10.1016/j.blre.2019.100650.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid leukemiaHard clinical outcomesClinical trial evidenceMeasurable residual diseaseResidual leukemic cellsRisk of relapseApprovable endpointsMRD statusDeep remissionMorphologic remissionMRD assessmentOverall survivalMRD levelsClinical outcomesDisease relapseInitial treatmentResidual diseaseTrial evidenceClinical trialsTreatment decisionsSurrogate endpointsBone marrowPreemptive interventionLeukemic cellsGut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia
Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan A, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clinical Infectious Diseases 2019, 71: 63-71. PMID: 31436833, PMCID: PMC7312220, DOI: 10.1093/cid/ciz777.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaInduction chemotherapyNeutrophil recoveryInfectious complicationsAML patientsMyeloid leukemiaAcute myeloid leukemia induction chemotherapyGut microbiome signaturesInfectious risk stratificationHematologic malignancy patientsExtended spectrum βSubsequent infectious complicationsStrong independent predictorHigher baseline levelsInduction therapyInfectious outcomesMalignancy patientsCarbapenem useIndependent predictorsTransplant settingAntibiotic administrationClinical outcomesRisk stratificationStool samplesMicrobiome signatures